Literature DB >> 1753108

IFN-alpha induces autocrine production of IL-6 in myeloma cell lines.

M Jourdan1, X G Zhang, M Portier, J M Boiron, R Bataille, B Klein.   

Abstract

IL-6 is a major tumor growth factor in human multiple myeloma. Myeloma cell lines, which have the same phenotypic characteristics and Ig gene rearrangements as the original fresh myeloma cells and whose growth is strictly dependent on exogenous IL-6 similar to fresh myeloma cells, have been reproducibly established. We show here that IFN-alpha stimulated the growth of five of six of these human myeloma cell lines by inducing an autocrine production of IL-6 in myeloma cells. Indeed, IFN-alpha induced IL-6 mRNA accumulation and IL-6 production in myeloma cells and the IFN-alpha-induced growth of these cells was inhibited by anti-IL-6 mAb. Moreover, IFN-alpha made possible the rapid emergence of autonomously growing myeloma cell sublines, which produced IL-6 as an autocrine growth factor. As IFN-alpha has a potential therapeutical interest for multiple myeloma, the present study opens up new directions for studying its effects on the myeloma clone in vivo.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1753108

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

Review 1.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

Review 2.  Viewpoint on the impact of interferon in the treatment of multiple myeloma: benefit for a small proportion of patients?

Authors:  J Bladé; J Esteve
Journal:  Med Oncol       Date:  2000-05       Impact factor: 3.064

Review 3.  IL-6-like cytokines and cancer cachexia: consequences of chronic inflammation.

Authors:  B E Barton
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

4.  Tumor necrosis factor is a survival and proliferation factor for human myeloma cells.

Authors:  M Jourdan; K Tarte; E Legouffe; J Brochier; J F Rossi; B Klein
Journal:  Eur Cytokine Netw       Date:  1999-03       Impact factor: 2.737

Review 5.  Alpha interferon: new associations in haematology/oncology. The Montpellier experience.

Authors:  J F Rossi
Journal:  Med Oncol       Date:  1995-03       Impact factor: 3.064

6.  Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells.

Authors:  Karène Mahtouk; Dirk Hose; Thierry Rème; John De Vos; Michel Jourdan; Jérôme Moreaux; Geneviève Fiol; Marc Raab; Eric Jourdan; Véronique Grau; Marion Moos; Hartmut Goldschmidt; Marion Baudard; Jean François Rossi; Friedrich W Cremer; Bernard Klein
Journal:  Oncogene       Date:  2005-05-12       Impact factor: 9.867

7.  BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.

Authors:  Jérôme Moreaux; Eric Legouffe; Eric Jourdan; Philippe Quittet; Thierry Rème; Cécile Lugagne; Philippe Moine; Jean-François Rossi; Bernard Klein; Karin Tarte
Journal:  Blood       Date:  2003-12-04       Impact factor: 22.113

8.  Brequinar sodium inhibits interleukin-6-induced differentiation of a human B-cell line into IgM-secreting plasma cells.

Authors:  K Tamura; J Woo; M T Bakri; A W Thomson
Journal:  Immunology       Date:  1993-08       Impact factor: 7.397

9.  An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis.

Authors:  Karène Mahtouk; Michel Jourdan; John De Vos; Catherine Hertogh; Geneviève Fiol; Eric Jourdan; Jean-François Rossi; Bernard Klein
Journal:  Blood       Date:  2003-10-23       Impact factor: 22.113

10.  Long-term survival in multiple myeloma: a single-center experience.

Authors:  Francesca Merchionne; Pasquale Procaccio; Franco Dammacco
Journal:  Clin Exp Med       Date:  2008-09-13       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.